Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 250 mg - tablet, uncoated - excipient ingredients: purified water; docusate sodium; gelatin; sodium benzoate; magnesium stearate; sodium starch glycollate; macrogol 400; isopropyl alcohol; maize starch; microcrystalline cellulose - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 500 mg - tablet, uncoated - excipient ingredients: gelatin; sodium benzoate; purified water; docusate sodium; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; maize starch; isopropyl alcohol; macrogol 400 - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: isopropyl alcohol; maize starch; purified water; gelatin; sodium starch glycollate; sodium benzoate; magnesium stearate; microcrystalline cellulose; macrogol 400; docusate sodium - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: purified talc; sucrose; lactose monohydrate; maize starch; calcium stearate; liquid paraffin - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; calcium stearate; liquid paraffin; sucrose; purified talc; maize starch - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 5 mg - tablet, uncoated - excipient ingredients: indigo carmine; maize starch; sucrose; purified talc; liquid paraffin; calcium stearate; lactose monohydrate - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 200 mg - tablet, uncoated - excipient ingredients: macrogol 400; maize starch; gelatin; sodium starch glycollate; isopropyl alcohol; docusate sodium; magnesium stearate; purified water; sodium benzoate; microcrystalline cellulose - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - medroxyprogesterone acetate 250 mg - tablet - 250 mg - medroxyprogesterone acetate 250 mg - medroxyprogesterone

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; purified talc; calcium stearate; liquid paraffin; maize starch; sunset yellow fcf; sucrose - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4.abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - medroxyprogesterone acetate 10mg;   - tablet - 10 mg - active: medroxyprogesterone acetate 10mg   excipient: calcium stearate lactose monohydrate liquid paraffin maize starch purified talc purified water sucrose - provera low dosage (2.5mg, 5mg and 10mg tablets) are indicated for: · diagnosis of primary and secondary amenorrhoea · treatment of dysfunctional (anovulatory) uterine bleeding · opposition of endometrial effects of estrogen in menopausal women being treated with estrogen (hormone replacement therapy [hrt]) · treatment of endometriosis.